Edition:
India

Organovo Holdings Inc (ONVO.OQ)

ONVO.OQ on NASDAQ Stock Exchange Global Market

1.38USD
22 Jan 2018
Change (% chg)

$-0.03 (-2.13%)
Prev Close
$1.41
Open
$1.40
Day's High
$1.40
Day's Low
$1.34
Volume
201,560
Avg. Vol
283,842
52-wk High
$3.85
52-wk Low
$1.32

Latest Key Developments (Source: Significant Developments)

Organovo posts Q3 loss per share $0.09
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Organovo Holdings Inc :Organovo announces fiscal second-quarter 2018 results; company shifts commercial focus to higher-value disease modeling opportunities and updates full-year fiscal 2018 outlook.Q2 loss per share $0.09.Q2 revenue $1.4 million versus I/B/E/S view $1.4 million.Sees FY 2018 revenue $4.5 million to $6.5 million.Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Organovo Holdings Inc ::Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease.Says Viscient is targeting early discovery work for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis​.  Full Article

Organovo signs exclusive distributor agreement with Japanese Cosmo Bio
Wednesday, 14 Dec 2016 

Organovo Holdings Inc - : Announced an exclusive distributor agreement with Cosmo Bio Co Ltd for its novoview preclinical services in Japan . Company will work with cosmobio's drug discovery services team for access to customers, support projects in Japanese biopharmaceutical industry .Press release - Organovo signs exclusive distributor agreement with Cosmo Bio (Japan).  Full Article

Organovo Q1 loss per share $0.09
Friday, 5 Aug 2016 

Organovo Announces Fiscal First : Quarter 2017 results; company affirms full-year fiscal 2017 and long-range outlook . Q1 revenue $900,000 . Q1 loss per share $0.09 .Affirmed fy 2017 outlook for total revenue, net cash utilization, initiation of commercial contracting for kidney tissue product.  Full Article

BRIEF-Organovo Holdings files for common stock offering pursuant to existing Controlled Equity Offering Sales Agreement (July 20)
Friday, 22 Jul 2016 

Corrects headline, first bullet to add dropped words 'pursuant to existing Controlled Equity Offering Sales Agreement'; Adds additional bullet to clarify company is not offering any additional shares.Organovo Holdings Inc : Files for offering up to $26.6 million, of shares of co's common stock pursuant to an existing Controlled Equity Offering Sales Agreement - SEC filing . Originally registered up to $33 million of shares pursuant to sales agreement under registration statement expiring on July 26, 2016 .Not registering any additional shares for sale pursuant to the Sales Agreement.  Full Article

Organovo Holdings files for common stock offering
Wednesday, 20 Jul 2016 

Organovo Holdings Inc : Files for offering up to $26.6 million, of shares of co's common stock - sec filing .Originally registered up to $33 million of shares pursuant to sales agreement under registration statement expiring on july 26, 2016.  Full Article

Organovo posts Q4 loss per share $0.09
Friday, 10 Jun 2016 

Organovo Announces Fiscal Fourth : Quarter and full-year 2016 results; company issues full-year fiscal 2017 outlook . Q4 loss per share $0.09 . Q4 revenue $500,000 .Sees total revenue of between $4 million and $6 million for fiscal-year 2017.  Full Article

BRIEF-Organovo Receives Orphan Designation From U.S. FDA For 3D Bioprinted Therapeutic Liver Tissue

* ORGANOVO RECEIVES ORPHAN DESIGNATION FROM U.S. FDA FOR 3D BIOPRINTED THERAPEUTIC LIVER TISSUE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY Source text for Eikon: Further company coverage: